Tesamorelin: research reference

Distinguish local mechanism from integrated effect. A whole-axis result needs its time context and cannot be summarized by a receptor name.

The GHRH receptor is a Gs protein-coupled receptor whose activation increases intracellular cyclic AMP in cellular models. The N-terminal modification reduces enzymatic degradation in in vitro studies.

The purity value is a product-label specification, not an assay result. A batch result can only be asserted from that batch’s certificate.

These names help identify the catalog entry. A descriptive label is not evidence of efficacy, and structural identity still requires appropriate documentation.

GHRH analog

Reconstitution: Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.

Storage: Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.

Personal protective equipment: Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.

The literature discussed here is unusual for this catalog: four of the six entries described in the research narrative rely on controlled human research rather than cell cultures. Three primary studies share random allocation, masking and an inactive comparator, but differ in size and the compartment measured. The 2007 trial included 412 volunteers and used computed tomography to follow abdominal adipose deposits. The 2014 study enrolled 50 volunteers and added liver-fat measurement. The 2019 study focused on liver fat, quantified by magnetic resonance spectroscopy, with follow-up extended to twelve months. All three examined adults with HIV infection and increased abdominal fat.

The fourth clinical publication, from 2026, supplied no new cohort: after a systematic search of five bibliographic databases, it pooled body composition, liver fat, a metabolic panel and adverse events. The other two references address different questions. One modeled population pharmacokinetics in 38 people followed for fourteen days. The other concerns analytical chemistry for antidoping: it incubated tesamorelin with three other GHRH analogs in vitro, isolated chain fragments and synthesized them as chromatographic reference standards. Sources: PMID 18057338; PMID 25038357; PMID 31611038; PMID 41545261; PMID 25358450; PMID 34665524.

The exposure analysis fitted an open, one-compartment population model, with input combining first-order and zero-order processes and first-order elimination. It reports plasma clearance and distribution volume with between-individual coefficients of variation, but the consulted record gives no half-life value. Within the examined range, age, body measurements, racial group and health condition did not shift model parameters. The fraction absorbed through the first-order process did differ between the beginning and end of fourteen-day follow-up.

Published chain-cleavage findings are in vitro and analytical: major degradation fragments were isolated and synthesized, indicating cleavage locations, although the stated objective was detection-method development. Albumin binding does not appear in the six references discussed. The stabilization described is chemical modification at the amino terminus, not attachment to a plasma protein. Sources: PMID 25358450; PMID 34665524.

The molecular scaffold reproduces the full 44-amino-acid chain of human hypothalamic growth hormone-releasing factor. The addition is a single trans-3-hexenoyl acyl group at its amino terminus, underlying the declared 5135.9 Da mass and CAS 218949-48-5. Development identifier TH9507 remains an alternate name and occurs in older literature.

The bibliography traces a multicenter trial of 412 volunteers in 2007; pharmacokinetic characterization published in 2015 using early-phase data rather than that cohort; liver-focused trials in 2014 and 2019; and a 2026 statistical synthesis whose search closed in July 2025. In 2021, the molecule also entered antidoping analytical research, where synthetic reference materials were made to study its detection. Sources: PMID 18057338; PMID 25038357; PMID 31611038; PMID 41545261; PMID 25358450; PMID 34665524.

The other catalog GHRH analogs are sermorelin, CJC-1295 No-DAC and CJC-1295 DAC. All share the described anterior-pituitary GHRH receptor target but differ in chain length and protection against enzymatic degradation. The other three start from fragment 1–29, while tesamorelin retains the full chain: declared masses include 3357.9 Da for sermorelin and 5135.9 Da for tesamorelin. Tesamorelin adds an amino-terminal acyl group; CJC-1295 No-DAC uses four internal substitutions; CJC-1295 DAC adds covalent albumin attachment; and sermorelin is the unchanged amidated fragment. Ipamorelin falls outside this structural comparison because its target in cellular models is another protein, GHSR-1a. The 2021 antidoping study is where all four GHRH analogs were measured using one method. Sources: PMID 34665524; PMID 25358450; PMID 41545261.

The human literature discussed comes from one clinical profile: adults with HIV infection and increased abdominal fat. There is no cohort outside that setting in this bibliography, so analogy does not support transfer. There is also no direct clinical comparison with sermorelin or either CJC-1295 variant despite their shared target. Published follow-up stops at twelve months. Exposure characterization rests on 38 people, a narrow population-model base, and does not examine covariates outside that range. The isolated in vitro fragments were synthesized for identification, not tested here for retained receptor affinity. The 2026 synthesis pools the same small set of trials rather than independent replications and inherits their limitations. Sources: PMID 18057338; PMID 31611038; PMID 41545261; PMID 25358450; PMID 34665524.